Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

TCS Named a Leader for Life Sciences R&D Strategic Consulting Services for Second Consecutive Time by IDC MarketScape

Posted On: 2018-09-24 17:16:50

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been named a Leader for the second consecutive time, in the IDC MarketScape for Worldwide Life Science R&D Strategic Consulting Services.1

According to the report, "TCS has extensive experience working with life science companies across all three sections of the industry: pharmaceutical, biotech, and medical devices." The report also noted, "Relative to other vendors discussed in this study and based on feedback from customer references, TCS received high marks for its technical skills, deep industry knowledge, competent end-to-end project delivery capabilities, and willingness to work as a partner to develop solution offerings on the cutting edge of life science innovation (e.g., TCS' Advanced Drug Development platform)."

"The life sciences industry continues to explore new growth avenues through technology-led innovations, proactive M&A pursuits, development of niche drugs, to enhance patient engagement and accelerate Business 4.0™ transformations," said Debashis Ghosh, President, Life Sciences and Healthcare, TCS. "This recognition by the /DC MarketScape is a validation of our vision, focus on innovation, and capabilities in consulting and advisory services."

TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. TCS offers a full set of services spanning advisory, digital transformation, and cognitive business operations in areas such as M&A and divestitures IT consulting, supply chain management, digitization of clinical trials, paperless and integrated lab environment, Blockchain-enabled clinical supply chain, AI enabled case processing, and discovery collaboration. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, Internet of Things and cloud to fully digitize life sciences value chain.

TCS' genomics and translational research offerings also deliver differentiated value to life sciences companies by combining bioinformatics analysis and DNA sequencing lab capabilities for emerging genomics-driven R&D initiatives.

Using TCS' Business 4.0™ thought leadership framework and deep contextual knowledge, its Life Sciences consultants help customers leverage digital technologies to gain a distinct edge in areas such as patient centricity, accelerated drug discovery, and clinical development.

"Strategic consulting in life sciences is more important than ever as industry transformation moves forward. Partnering with a strategic consulting service provider is a core strategy for success. TCS' Business 4.0™ thought leadership framework, technical and domain focus and ability to successfully partner with customers for development of cutting-edge life science innovations, makes it a preferred transformation partner to address strategic consulting needs," said Alan S. Louie, Research Director, IDC Health Insights Life Science R&D Strategies and Technology Research.

"Our Business 4.0™ vision, vast technical c;md domain knowledge, investments in future-ready solutions, and next generation platform solutions, position us as a preferred consulting partner for our customers in the life sciences industry," added Debashis Ghosh.

Shares of TATA CONSULTANCY SERVICES LTD. was last trading in BSE at Rs.2198.7 as compared to the previous close of Rs. 2103.8. The total number of shares traded during the day was 299610 in over 15149 trades.

The stock hit an intraday high of Rs. 2214.15 and intraday low of 2098.3. The net turnover during the day was Rs. 650156496.

1 IDC MarketScape: Worldwide Life Science R&D Strategic Consulting Services 2018 Vendor Assessment, Doc #US44159218, August 2018


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Strides receives USFDA approval for Gabapentin Capsules

JSW Steel Ltd board to consider raising long term resources on Oct 25, 2018

HDFC Bank announces Q2 FY19 results

Srei Infrastructure Finance Ltd clarifies on rumours

UCO Bank designates Sri Ram Kumar as CFO

Triveni Turbine Ltd board to approve 2nd quarter results on Nov 1, 2018

Nitin Spinners Ltd board to consider second quarter results on Oct 31, 2018

Deepak Spinners Ltd board to announce 2nd quarter results on Nov 5, 2018

HPL Electric & Power Ltd board to approve Q2 FY19 results on Oct 29, 2018

Kirloskar Pneumatic Company Ltd board to consider Q2, H1 results on Nov 2, 2018

Welspun Enterprises Ltd calls for board meeting on Oct 30, 2018 to approve Q2 results

Lakshmi Mills Company Ltd board to announce Q2 FY19 results on Nov 14, 2018

Shreyans Industries Ltd board to consider quarterly results on Nov 13, 2018

Bank of Maharashtra Ltd calls for board meeting on Oct 30, 2018

Maithan Alloys Ltd board to approve Q2, H1 results on Oct 29, 2018

Fine Organic Industries Ltd board to announce 2nd quarter results on Nov 2, 2018

Wonderla Holidays Ltd board to consider Q2 FY19 results on Oct 29, 2018

Dena Bank Ltd calls for board meeting on Oct 30, 2018

Adani Enterprises Ltd board to announce quarterly results on Oct 31, 2018

Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

Adani Green Energy Ltd board to approve 2nd quarter results on Oct 31, 2018

Adani Power Ltd board to consider Q2 results on Oct 31, 2018

Tube Investments of India Ltd calls for board meeting on Nov 2, 2018

Edelweiss Financial Services Ltd to announce Q2 FY19 results on Oct 26, 2018

Zydus Wellness Ltd calls for board meeting on Nov 2, 2018 to consider Q2 results

Aurionpro Solutions Ltd board to consider 2nd quarter results on Oct 27, 2018

Just Dial Ltd board to approve Q2 results on Oct 29, 2018

Bajaj Electricals Ltd board to announce Q2, H1 FY19 results on Nov 1, 2018

Voltamp Transformers Ltd board to consider Q2 FY19 results on Nov 1, 2018

TGV Sraac Ltd board to approve second quarter results on Oct 27, 2018

JSW Energy Ltd board to announce 2nd quarter results on Nov 2, 2018

Pioneer Embroideries Ltd calls for board meeting on Oct 28, 2018

JSW Holdings Ltd board to consider Q2 results on Nov 3, 2018

Bhansali Engineering Polymers Ltd Q2 net profit slides to Rs. 16.88 crores

Sadhana Nitrochem Ltd continues its dream performance in Q2 FY19

NELCO Ltd Q2 net profit jumps to Rs. 10.09 crores

Bhageria Industries Ltd Q2 PAT zooms to Rs. 28.21 crores

MPS Ltd Q2 FY19 consolidated net up at Rs. 18.67 crores

Smruthi Organics Ltd Q2 PAT jumps Y-o-Y to Rs. 1.03 crore

HDFC Bank Ltd Q2 FY19 net profit climbs to Rs. 5005.73 crores

Pudumjee Paper Products Ltd reports higher Q2 net profit of Rs. 5.75 crore

Srikalahasthi Pipes Limited board to approve Q2 FY19 results on Oct 31, 2018

Sasan Power Limited wins arbitration award against NACC

EROS International Media Ltd board to announce Q2, H1 FY19 results on Oct 26, 2018

OnMobile Global Ltd board to consider 2nd quarter results on Oct 29, 2018

Bodal Chemicals Ltd calls for board meeting on Oct 25, 2018

Butterfly Gandhimathi Appliances Ltd board to announce second quarter results on Oct 31, 2018

Merck Ltd board to approve quarterly results on Oct 30, 2018

Savita Oil Technologies Ltd board to consider Q2 FY19 results on Nov 3, 2018

VTM Ltd posts jump in Q2 PAT to Rs. 3.93 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018